Middle East and Turkey Hemophilia Treatment Market, by Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and b

Middle East and Turkey Hemophilia Treatment Market, by Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Country (Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hemophilia is rare disorder, in which in which the blood does not clot properly. In this case, bleeding after an injury takes longer duration to clot. This condition is well treated with medications such as recombinant coagulation factor, plasma derived coagulation factor, antifibrinolytic agents, and desmopressin. Generally hemophilia occurs in middle age and geriatric population, and in women after child birth. Hemophilia is characterized by the lower levels of factors in the blood, which results in constant bleeding for longer duration after an injury.
Market Dynamics
Increasing incidences of hemophilia cases is expected to drive the Middle East and Turkey hemophilia treatment market growth. For instance, according to the Annual Global Survey’s 2016 data published by World Federation of Hemophilia, around 184,723 number of people globally suffered from hemophilia in 2016. Among this, 149,764 and 29,712 patients accounted for Hemophilia A and Hemophilia B, respectively.
Rising collaboration activities among the key players in pharmaceutical industry to develop novel hemophilia treatment options is expected to drive growth of the market. For instance, in May 2017, Sangamo Therapeutics, Inc. and Pfizer Inc. entered into a collaboration for the development and commercialization of Hemophilia A gene therapy programs, which include Sangamo’s SB-525 candidate, which may benefit patients suffering from Hemophilia A.
Key features of the study:
This report provides in-depth analysis of the Middle East and Turkey hemophilia treatment, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the Middle East and Turkey hemophilia treatment based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, government initiatives, technological upgradation, market expansion, and marketing tactics
The Middle East and Turkey hemophilia treatment report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for Middle East and Turkey hemophilia treatment, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Middle East and Turkey Hemophilia Treatment, By Product Type:
Recombinant Coagulation Factor
Plasma Derived Coagulation Factor
Antifibrinolytic Agents
Desmopressin
Middle East and Turkey Hemophilia Treatment, By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C
Middle East and Turkey Hemophilia Treatment, By Country:
Turkey
By Product Type:
Recombinant Coagulation Factor
Plasma Derived Coagulation Factor
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C
Egypt
By Product Type:
Recombinant Coagulation Factor
Plasma Derived Coagulation Factor
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C
Israel
By Product Type:
Recombinant Coagulation Factor
Plasma Derived Coagulation Factor
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C
Saudi Arabia
By Product Type:
Recombinant Coagulation Factor
Plasma Derived Coagulation Factor
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C
Rest of Latin America
UAE
By Product Type:
Recombinant Coagulation Factor
Plasma Derived Coagulation Factor
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C
Rest of Middle East
By Product Type:
Recombinant Coagulation Factor
Plasma Derived Coagulation Factor
Antifibrinolytic Agents
Desmopressin
By Disease Indication:
Hemophilia A
Hemophilia B
Hemophilia C
Company Profiles
Takeda Pharmaceutical Company Limited*.
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Sanofi S.A.
Octapharma AG
Swedish Orphan Biovitrum AB
Baxter International Inc.
Biogen Inc.
Bayer AG
CSL Behring
Ferring B.V.
Pfizer, Inc.
Kedrion
Novo Nordisk A/S
Grifols S.A
Sangamo Therapeutics, Inc.
Spark Therapeutics, Inc.
“*” marked represents similar segmentation in other categories in the respective section.